Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Methylphenidate Extended Release in Patients With Schizophrenia
NCT05414058Phase 2Completed
- Sponsor
- The Royal Ottawa Mental Health Centre
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methylphenidate hydrochloride extended-release chewable tablet in schizophrenia and schizoaffective disorder (2 arms), sponsored by The Royal Ottawa Mental Health Centre. Primary endpoint: Virtual Reality Functional Capacity Assessment Tool at 12 weeks. Started Sep 2022; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT05414058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414058.